Flt3L has shown promise as a biomarker of ICI responsiveness in other cancers, such as melanoma, by promoting conventional type 1 dendritic cell (cDC1) populations associated with anti‐tumour immunity [14, 15, 16, 17]. The gene discussed is FLT3LG; the disease is melanoma.